Cargando…
Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose
BACKGROUND AND OBJECTIVE: Women with postpartum depression (PPD) may expose their infants to antidepressants via breast milk. Brexanolone is the only FDA-approved antidepressant specifically indicated for the treatment of PPD. This open-label, phase Ib study of healthy lactating volunteers assessed...
Autores principales: | Wald, Jeffrey, Henningsson, Anja, Hanze, Eva, Hoffmann, Ethan, Li, Haihong, Colquhoun, Helen, Deligiannidis, Kristina M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439988/ https://www.ncbi.nlm.nih.gov/pubmed/35869362 http://dx.doi.org/10.1007/s40262-022-01155-w |
Ejemplares similares
-
Brexanolone as adjunctive therapy in super‐refractory status epilepticus
por: Rosenthal, Eric S., et al.
Publicado: (2017) -
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017) -
Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy
por: Reddy, Doodipala Samba, et al.
Publicado: (2023) -
Efficacy of brexanolone in postpartum depression
por: Rodríguez Mercado, C. M.
Publicado: (2023) -
Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’
por: Shukla, Ajay Kumar, et al.
Publicado: (2021)